What We Do

Translational Strategy & Asset Evaluation

A clear, independent view of what an asset is worth and who it is for.

Before you license, acquire or invest, you need to know whether the science will hold up in patients.

We assess an asset along its whole path, from preclinical data to clinical results and real-world use. We look at how the drug works, what the trials show, and how it would fit in practice.

You get:

  • The signals that matter clinically.
  • The patients most likely to benefit.
  • Where the asset can stand apart from competitors.

Where it helps, we use biomarkers and patient stratification to support precision medicine.

Request a call

See all case studies

Tell us what you’re working on

Initial discussions are confidential and without obligation. Send a short note and we will reply.

Request a call